Patents by Inventor Aaron Ken Sato

Aaron Ken Sato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding VEGF/DLL4 binding agents
    Patent number: 9574009
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: February 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Antibodies against human FZD5 and FZD8
    Patent number: 9573998
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 21, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Polynucleotides Encoding VEGF/DLL4 Binding Agents
    Publication number: 20160362499
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 15, 2016
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
    Patent number: 9505832
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: November 29, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20160326259
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: January 21, 2016
    Publication date: November 10, 2016
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Chartes Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Jagged-binding agents and uses thereof
    Patent number: 9416178
    Abstract: The present invention relates to Jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human Jagged1 or human Jagged2 and modulate Jagged activity. The present invention further provides methods of using agents that modulate the activity of Jagged, such as antibodies that specifically bind Jagged, and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 16, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • VEGF binding antibodies
    Patent number: 9376488
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: June 28, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Monoclonal antibodies against frizzled
    Patent number: 9273139
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 1, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20150232554
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: January 26, 2015
    Publication date: August 20, 2015
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20150197563
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 16, 2015
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • JAGGED-BINDING AGENTS AND USES THEREOF
    Publication number: 20150197561
    Abstract: The present invention relates to Jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human Jagged1 or human Jagged2 and modulate Jagged activity. The present invention further provides methods of using agents that modulate the activity of Jagged, such as antibodies that specifically bind Jagged, and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: July 16, 2015
    Inventors: AUSTIN L. GURNEY, TIMOTHY CHARLES HOEY, AARON KEN SATO, ALEXANDRA LAZETIC, ZHIMIN JI
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20150183878
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 21, 2014
    Publication date: July 2, 2015
    Inventors: Austin GURNEY, Aaron Ken Sato, Maureen Fitch-Bruhns
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20150098949
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 9, 2015
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, CHRISTOPHER JOHN BOND
  • Monoclonal antibody that binds human notch2 and notch3
    Patent number: 8980260
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Polynucleotides encoding for frizzled-binding agents and uses thereof
    Patent number: 8975044
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 10, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Polynucleotides encoding Notch receptor antibodies
    Patent number: 8945873
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Jagged-binding agents and uses thereof
    Patent number: 8945569
    Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • Antibodies that bind the glutamate ligand binding region of NOTCH3
    Patent number: 8921106
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: December 30, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Maureen Fitch-Bruhns
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 8858941
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 14, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • ANTIBODIES THAT BIND THE GLUTAMATE LIGAND BINDING REGION OF NOTCH3
    Publication number: 20130323257
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: May 9, 2013
    Publication date: December 5, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Maureen Fitch-Bruhns